Canada markets closed

Bellerophon Therapeutics, Inc. (BLPH)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.92000.0000 (0.00%)
As of 09:33AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.9200
Open0.9200
Bid0.9200 x 4000
Ask0.9980 x 3200
Day's Range0.9200 - 0.9360
52 Week Range0.6700 - 5.9500
Volume8,373
Avg. Volume54,752
Market Cap8.782M
Beta (5Y Monthly)-0.17
PE Ratio (TTM)N/A
EPS (TTM)-1.8850
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.50
  • GlobeNewswire

    Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference

    WARREN, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced a poster presentation at the upcoming American Thoracis Society (ATS) 2022 International Conference, being held May 13-18, 2022, in San Francisco, CA. Presentation Details Session C103: It's not just about IPFPoster Title: A Phase 2 Trial of INOpulse in

  • GlobeNewswire

    Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results

    WARREN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2022. “We remain focused on the continued advancement of our late-stage INOpulse® inhaled nitric oxide therapy platform for the treatment of fibrotic interstit

  • GlobeNewswire

    Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results

    WARREN, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the year ended December 31, 2021. “The development of our INOpulse® inhaled nitric oxide therapy platform remains our foremost priority, in order to address the significant unmet needs in fib